Column: Walmart’s low-priced insulin shows what a rational drug market should look like

Mark V. Pauly of the Wharton School weighed in on Walmart’s new, lower cost insulin. The offering “may be a PR or traffic-building exercise,” he said, but could ultimately pressure drug companies to lower their prices.

・ From Los Angeles Times